Fennec Banks On EMA’s Seldom-Used PUMA For Sodium Thiosulfate

Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.

Ear of child
The PUMA pathway is designed to incentivize companies to develop medicines exclusively for use in children • Source: Shutterstock

Fennec Pharmaceuticals is counting on the European Medicines Agency’s rarely used pediatric use marketing authorization (PUMA) pathway to pave its way to winning pan-EU approval for the unique formulation of sodium thiosulfate it is developing to prevent cisplatin-induced hearing loss in children.

The marketing application for the product was recently validated by the EMA, which this month added the drug to its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet